In a ruling that placed on pause an 11-year-old whistleblower suit against Pfizer, a federal judge has granted an immediate appeal on three issues that weigh into unsettled areas of law related to the False Claims Act.
U.S. District Judge R. Barclay Surrick of the Eastern District of Pennsylvania on June 22 granted Pfizer’s motion seeking an interlocutory appeal to the U.S. Court of Appeals for the Third Circuit in United States v. Pfizer, a qui tam case over allegations that the drugmaker illegally marketed the anti-fungal medication, Vfend, for off-label use.
